title: Next-generation dengue vaccines: novel strategies currently under development.
abstract: Dengue has become the most important arboviral infection worldwide with more than 30 million cases of dengue fever estimated to occur each year. The need for a dengue vaccine is great and several live attenuated dengue candidate vaccines are proceeding through clinical evaluation. The need to induce a balanced immune response against all four DENV serotypes with a single vaccine has been a challenge for dengue vaccine developers. A live attenuated DENV chimeric vaccine produced by Sanofi Pasteur has recently entered Phase III evaluation in numerous dengue-endemic regions of the world. Viral interference between serotypes contained in live vaccines has required up to three doses of the vaccine be given over a 12-month period of time. For this reason, novel DENV candidate vaccines are being developed with the goal of achieving a protective immune response with an immunization schedule that can be given over the course of a few months. These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed.
authors: Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N. Broadway, Room 251, Baltimore, MD 21205, USA. adurbin@jhsph.edu
authors: Anna P
authors: AP
authors: Durbin
authors: Stephen S
authors: SS
authors: Whitehead
mesh_terms: D000956:Antigens, Viral / Q000276:immunology*; D003715:Dengue / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000235:genetics / Q000276:immunology*; D003716:Dengue Virus / Q000235:genetics / Q000276:immunology*; D005822:Genetic Vectors; D006801:Humans; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014762:Viral Interference
chemical_list: D000956:Antigens, Viral; D053059:Dengue Vaccines; D014613:Vaccines, Attenuated; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic